Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology

Abstract #2604: HMGA2 is a novel prognostic factor in melanoma

Leon Raskin, Timothy Johnson, Douglas Fullen, Thomas Giordano, Michelle Vinco, Bhramar Mukherjee, Jaeil Ahn, Eduardo Vilar and Stephen Gruber
Leon Raskin
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Johnson
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas Fullen
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Giordano
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Vinco
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhramar Mukherjee
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaeil Ahn
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduardo Vilar
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Gruber
University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

BACKGROUND: The molecular genetic alterations contributing to the pathogenesis of melanoma are incompletely defined and few independent prognostic features have been identified beyond the pathologic characteristics of the primary tumor. Early stage melanoma is frequently curable, in contrast to the inferior prognosis of melanomas with regional lymph nodes involvement and the incurability of distant metastatic disease. The identification of novel tumor-specific markers may improve our understanding of melanoma progression and prognostic accuracy. METHODS: To find differentially expressed genes that can distinguish melanoma from normal tissue, we performed a whole genome expression profiling of 46 primary melanoma samples, 12 regional or distant metastases, and 16 normal skin samples using Affymetrix U133 2.0 Plus array. RESULTS: HMGA2, previously unrecognized in the pathogenesis of melanoma, is an oncogene and transcription factor that is significantly upregulated both in primary melanoma and metastatic melanoma (p-values=1.2x10-7 and 9x10-5) compared to normal skin. Overexpression of HMGA2 is associated with BRAF/NRAS mutations (Odds ratio = 22.7, 95% confidence interval (CI) = 4.7-109.0, p= <0.0001). Survival analysis using Cox multivariable model and stratified log-rank test showed that expression levels of HMGA2 are significantly associated with disease-free survival (hazard ratio (HR) = 3.5, 95% CI = 1.2-10.1, p=0.0195), overall survival (log-rank p=0.0093), and distant metastases-free survival (HR=4.8, 95% CI = 1.2-18.6, p=0.0239). The median follow-up was 4 years in the primary melanoma group. In addition, the multivariate survival analysis, which included AJCC stage, demonstrated that overexpression of HMGA2 in primary melanoma is an independent predictor of regional lymph node metastases and local recurrence, even after adjustment for BRAF/NRAS mutations. CONCLUSIONS: HMGA2 is a transcription factor that is expressed during embryogenesis, is absent or undetectable in normal tissue, and is highly overexpressed in melanoma. HMGA2 expression is also strongly associated with the presence of regional and distant metastases and warrants further investigation as a biomarker predictive of lymph node metastases in prospective clinical trials. HMGA2 expression is an independent predictor of disease-free survival and overall survival in melanoma.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2604.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #2604: HMGA2 is a novel prognostic factor in melanoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #2604: HMGA2 is a novel prognostic factor in melanoma
Leon Raskin, Timothy Johnson, Douglas Fullen, Thomas Giordano, Michelle Vinco, Bhramar Mukherjee, Jaeil Ahn, Eduardo Vilar and Stephen Gruber
Cancer Res May 1 2009 (69) (9 Supplement) 2604;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #2604: HMGA2 is a novel prognostic factor in melanoma
Leon Raskin, Timothy Johnson, Douglas Fullen, Thomas Giordano, Michelle Vinco, Bhramar Mukherjee, Jaeil Ahn, Eduardo Vilar and Stephen Gruber
Cancer Res May 1 2009 (69) (9 Supplement) 2604;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cellular and Molecular Biology

  • Abstract SY29-01: Functions of wild type and mutant p53
  • Abstract SY34-02: The impact of O2 availability on human cancer
  • Abstract SY19-01: Cell to cell variability in the responses of tumor cells to death ligands
Show more 3

Oncogenomics 3: Non-coding RNAs, microRNAs, siRNAs, and Functional Genomics -- Poster Presentations - Proffered Abstracts

  • Abstract #2600: CD34+ obtained from high Sokal risk chronic myeloid leukemia (CML) patients (pts) expresses gene profiles (GEP) significantly different from CD34+ obtained from low and intermediate Sokal risk patients
  • Abstract #2586: High-throughput RNAi screening for the identification of genes involved in proliferation and survival of prostate cancer cells
  • Abstract #2597: High expression of ncRAN, a long non-coding RNA mapped to 17q25, is associated with aggressiveness and poor prognosis of neuroblastoma
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement